TABLE 2.
Clinicopathological characteristics according to POLE mutation status.
| Characteristics | ZZ cohort | TCGA cohort | ||||||
|---|---|---|---|---|---|---|---|---|
| POLE EDM (n = 7) | POLE non-EDM (n = 14) | POLE WT (n = 251) | P | POLE EDM (n = 9) | POLE non-EDM (n = 24) | POLE WT (n = 466) | P | |
| Age, median (range) | 40.0 (34.0–52.0) | 49.0 (35.75–59.5) | 53.0 (46.0–64.0) | 0.018 | 65.0 (51.5–76.5) | 59.0 (49.0–70.8) | 68.0 (57.0–75.0) | 0.183 |
| TMB (Mut/mb), median (range) | 175.9 (28.0--) | 24.0 (19.6–40.2) | 8.6 (5.4–14.6) | 0.012 | 115.3 (68.4–188.5) | 64.2 (39.3–98.3) | 3.4 (2.7–4.9 | <0.001 |
| Sex | 0.455 | 0.013 | ||||||
| Male | 4 (57.1%) | 10 (71.4%) | 134 (53.4%) | 8 (88.8%) | 8 (33.3%) | 248 (53.2%) | ||
| Female | 3 (42.9%) | 4 (28.5%) | 117 (46.6%) | 1 (11.1%) | 16 (66.6%) | 218 (46.7%) | ||
| MSI status | <0.001 | <0.001 | ||||||
| MSI-H | 2 (28.6%) | 9 (64.2%) | 29 (11.6%) | 4 (44.4%) | 16 (66.6%) | 47 (10.0%) | ||
| MSI-L/MSS | 5 (71.4%) | 4 (28.5%) | 212 (84.5%) | 5 (55.5%) | 7 (29.1%) | 417 (89.4%) | ||
| Unknown | 0 | 1 (7.1%) | 10 (4.0%) | 0 | 1 (4.1%) | 2 (0.4%) | ||
| Pathology | 0.050 | 0.004 | ||||||
| Adenocarcinoma | 5 (71.4%) | 13 (92.8%) | 234 (93.2%) | 8 (88.8%) | 16 (66.6%) | 421 (90.3%) | ||
| Mucinous adenocarcinoma | 2 (28.5%) | 1 (7.1%) | 13 (5.1%) | 1 (11.1%) | 8 (33.3%) | 45 (9.6%) | ||
| Others | 0 | 0 | 4 (1.5%) | 0 | 0 | 0 | ||
| Location | 0.001 | 0.112 | ||||||
| Left colon | 6 (85.7%) | 5 (35.7%) | 68 (27.0%) | 1 (11.1%) | 2 (8.3%) | 105 (22.5%) | ||
| Right colon | 1 (14.2%) | 7 (50.0%) | 64 (25.4%) | 4 (44.4%) | 12 (50.0%) | 145 (31.1%) | ||
| Rectum | 0 | 2 (14.2%) | 119 (47.4%) | 2 (22.2%) | 3 (12.5) | 125 (26.8%) | ||
| Unknown | 0 | 0 | 0 | 2 (22.2%) | 7 (29.2%) | 91 (19.5%) | ||
| Grade | 0.062 | — | ||||||
| G2 | 3 (42.9%) | 9 (64.2%) | 198 (78.9%) | — | — | — | ||
| G3 | 3 (42.9%) | 2 (14.2%) | 34 (13.5%) | — | — | — | ||
| Unknown | 1 (14.3%) | 3 (21.4%) | 19 (7.6%) | — | — | — | ||
| Stage | 0.536 | 0.207 | ||||||
| I | 1 (14.3%) | 1 (7.1%) | 20 (8.0%) | 0 | 4 (16.6%) | 86 (18.4%) | ||
| II | 3 (42.9%) | 3 (21.4%) | 51 (20.3%) | 6 (66.6%) | 13 (54.1%) | 165 (35.4%) | ||
| III | 2 (28.6%) | 3 (21.4%) | 56 (22.3%) | 2 (22.2%) | 4 (16.6%) | 141 (30.2%) | ||
| IV | 1 (14.3%) | 7 (50.0%) | 118 (47.0%) | 0 | 2 (8.3%) | 64 (13.7%) | ||
| NA | 0 | 0 | 6 (2.4%) | 1 (11.1%) | 1 (4.1%) | 0 | ||
| Depth of tumor invasion | 0.744 | 0.334 | ||||||
| T1 | 0 | 0 | 2 (0.8%) | 0 | 1 (4.1%) | 16 (3.4%) | ||
| T2 | 1 (14.3%) | 1 (7.1%) | 52 (20.7%) | 1 (11.1%) | 4 (16.6%) | 87 (18.6%) | ||
| T3 | 5 (71.4%) | 8 (57.1%) | 143 (57.0%) | 7 (77.7%) | 13 (54.1%) | 318 (68.2%) | ||
| T4 | 1 (14.3%) | 2 (14.2%) | 25 (10.0%) | 1 (11.1%) | 6 (25.0%) | 45 (9.6%) | ||
| NA | 0 | 3 (21.4%) | 29 (11.6%) | 0 | 0 | |||
| Lymph node metastases | 0.728 | |||||||
| N0 | 5 (71.4%) | 6 (42.8%) | 94 (37.5%) | 7 (77.7%) | 18 (75.0%) | 264 (56.6%) | 0.305 | |
| N1 | 1 (14.3%) | 3 (21.4%) | 54 (21.5%) | 2 (22.2%) | 3 (12.5%) | 120 (25.7%) | ||
| N2 | 1 (14.3%) | 3 (21.4%) | 72 (28.7%) | 0 | 3 (12.5%) | 81 (17.3%) | ||
| Unknown | 0 | 2 (14.2%) | 31 (12.4%) | 0 | 0 | 1 (0.2%) | ||
| Hazard factor | 0.181 | — | ||||||
| no | 6 (85.7%) | 7 (50.0%) | 84 (33.5%) | — | — | — | ||
| Perineural invasion | 0 | 0 | 37 (14.7%) | — | — | — | ||
| Vascular carcinoma embolus | 1 (14.3%) | 1 (7.1%) | 44 (17.5%) | — | — | — | ||
| Both | 0 | 2 (14.2%) | 43 (17.1%) | — | — | — | ||
| Unknown | 0 | 4 (28.5%) | 43 (17.1%) | — | — | — | ||